The FDA recently approved the use of Wegovy (semaglutide) for the treatment of obesity in teens ages 12 years and older. It is the first and only weekly anti-obesity medication approved for adolescents. Initial BMI must be at or above the 95th percentile to qualify. In clinical trials, this once weekly subcutaneous injection has shown to reduce BMI by an average of 16.1% in teens ages 12+.
Obesity affects nearly 70% of adolescents and of those with weight issues, 90% will continue to struggle with weight and/or weight-related health problems into adulthood. As the rate of teen obesity continues to rise, we are finally a step in the right direction. Having this tool provides an option for early intervention, making weight management and behavior changes much more impactful. Weekly weight loss injections give teens the opportunity to learn behaviors that will allow them to lose weight and keep it off, reducing their risks of adulthood obesity.
If your teen meets the criteria (ages 12+ and BMI >95th percentile), schedule an initial consultation today for personalized care plans to help your child have a brighter future.
